Welcome to the Michigan Cancer Research Fund (MCRF)
The MCRF was established in 2008 by a group of cancer-concerned philanthropists to fund approved critical cancer research projects that would otherwise remain unfunded.
Welcome to the Michigan Cancer Research Fund (MCRF)
The MCRF was established in 2008 by a group of cancer-concerned philanthropists to fund approved critical cancer research projects that would otherwise remain unfunded.
Welcome to the Michigan Cancer Research Fund (MCRF)
The MCRF was established in 2008 by a group of cancer-concerned philanthropists to fund approved critical cancer research projects that would otherwise remain unfunded.
Our research goal is simple — find answers that help save lives from cancer. Our strategy for funding research is just as straightforward — fund the most innovative cancer research. In fact, we’ve helped make possible many of the major cancer research breakthroughs since 1946.
Our grants fund high impact research conducted by hundreds of promising scientists and health care professionals—primarily early in their careers—at institutions across the United States.
Institution: | Grants: | Amount: |
Michigan State University | 1 | $1,779,750 |
Van Andel Research Institute | 2 | $967,500 |
Wayne State University |
2 | $1,573,500 |
University of Michigan |
14 | $9,494,500 |
(grant totals are as of Aug 24, 2022)
Welcome to the Michigan Cancer Research Fund (MCRF)
The MCRF was established in 2008 by a group of cancer-concerned philanthropists to fund approved critical cancer research projects that would otherwise remain unfunded.
The American Cancer Society (ACS) is the largest private funder of cancer research, having more than $403 million currently invested in grants. With its commitment to beginning researchers, the ACS continues to provide substantial cancer research funding across the United States to scientists in the early stages of their careers, ensuring that many of the best young minds choose careers in cancer research.
The ACS has a goal of funding all exceptional research grants received. Presently, ACS is only able to fund about 50% of the top-ranked research projects approved for funding following peer review. As a result, promising researchers and projects that have the potential to reduce the burden of cancer are put on hold due to budget constraints. The shortfall of funding means that innovative cancer research may not be conducted, and the careers of promising young investigators could be in jeopardy. The COVID-19 pandemic, which has impacted virtually every aspect of cancer care and research, has heightened the need to narrow the gap between the number of ACS grant applications approved for funding and those funded.
The ACS cancer-concerned philanthropists created the Michigan Cancer Research Fund (MCRF) with the goal of funding ACS approved research projects led by investigators at Michigan-based institutions that would otherwise remain unfunded.
Mr. and Mrs. William Y. Campbell
Charles E. Becker and Michelle S. Becker Foundation
John A. and Marlene L. Boll Foundation
Kristine Mestdagh, Executive Director
W.Y. Campbell Family Foundation
Mr. and Mrs. William Y. Campbell
Cendrowski Corporate Advisors
Mr. Harry Cendrowski and Ms. Maureen Nulty
Gary L. and Kay Cowger
Mr. and Mrs. Brian A. Demkowicz
Mrs. Anne Ford Dingeman
Mr. and Mrs. David Fischer, Jr.
Mr. and Mrs. Michael R. Fisher
Mr. and Mrs. Dainforth B. French, Jr.
Mr. and Mrs. Kenneth A. Fruehauf
Chauncey and Marion D. McCormick Family Foundation
Mr. Ian Hunt, Trustee
Atanas Ilitch Osteosarcoma Foundation
Mr. and Mrs. Atanas Ilitch
Helen L. Kay Charitable Private Foundation
Mr. and Mrs. J. Claibourne Kelly
Mr. and Mrs. Robert G. Liggett, Jr.
Mr. and Mrs. William F. McKinley
Mr. and Mrs. James B. Nicholson
Mrs. Diane Graham Platt
Mr. and Mrs. Scott A. Reilly
Mr. and Mrs. William W. Shelden, Jr.
Mr. Jeffrey Smith and Mrs. Lisa Vallee-Smith
The Mary G. Stange Charitable Trust
Mr. and Mrs. David C. Stone
Mr. and Mrs. James P. TenBroek
TWO MEN AND A TRUCK®
Mr. and Mrs. Mark Valade
Mr. and Mrs. Michael A. Vlasic
Wayne and Joan Webber Foundation
Mr. and Mrs. Wayne Webber
Dr. and Dr. David Wu
Welcome to the Michigan Cancer Research Fund (MCRF)
The MCRF was established in 2008 by a group of cancer-concerned philanthropists to fund approved critical cancer research projects that would otherwise remain unfunded.
Dr. Humphries earned his B.S. in Biology at Saginaw Valley State University, and his PhD in Cellular and Molecular Biology from Michigan State University. He is currently a postdoctoral research fellow in the Department of Radiology at the University of Michigan.
His research uses a multidisciplinary approach to identify the molecular mechanisms that drive tumor recurrence and metastasis, with the goal of elucidating novel therapeutic targets for breast cancer.
Microfluidic-based Identification of Drivers of Tumor-initiating Cells
​Breast cancer-related deaths will continue to rise if new steps in treatment are not taken. Recent studies have shown that tumor formation and cancer progression are driven by tumor-initiating cells (TICs, also known as cancer stem cells (CSCs)). TICs are a small subpopulation of the tumor that greatly contribute to treatment failure and promote disease recurrence due to their enhanced migration and resistance to commonly used chemotherapeutics (chemoresistance). Therefore, successful cancer treatment depends on effective targeting of TICs.
Our long-term goal is to identify the molecular drivers of TICs to discover new targets for cancer therapy. One of the major challenges currently facing TIC biology is the efficient isolation and recovery of TICs for study. Current techniques for isolating breast cancer TICs revolve around internal or cell surface markers. However, these techniques have several major setbacks including a lack of specificity for only TICs, and the fact that these markers do not directly correlate with TIC function or even patient prognosis and outcome. Therefore, there is an urgent need to improve techniques used to identify and isolate TICs for further study.
To address this deficiency, we have developed a device which functionally isolates TICs based upon their enhanced ability to migrate. Using our device, we have identified a unique set of migratory cells that have a greater tumor-initiating potential than matched non-migratory cells. One of the key differences between these cells is the decreased expression of phosphatidylserine decarboxylase (PISD) in migratory cells, which suggests PISD as a potential regulator of TICs. PISD is located within the mitochondria of cells, and consistent with this our preliminary results demonstrate that PISD regulates the energy and cellular metabolism of cells. We also found that increasing PISD expression reduces the TIC population in breast cancer cell lines, which suggests that PISD regulates TIC biology through mitochondria and metabolism.
The goals of this project are to:
Overall, this research will provide the foundation for mechanisms that drive TICs, and will also identify novel therapeutic options for patients with recurrent or metastatic disease.
Find more information about Dr. Humphries, including published work.
Dr. Kaitlin Basham obtained her B.S. in biology from Saint Mary's College of California in 2008. She completed her Ph.D. in 2014 at the Huntsman Cancer Institute at the University of Utah. For her postdoctoral fellowship, Dr. Basham moved to the University of Michigan and worked in the Department of Internal Medicine. In January 2021, she returned to the Huntsman Cancer Institute as an assistant professor of Oncological Sciences.
Her research is aimed at determining how the loss of the ZNFR3/RNF43 genes disrupts equilibrium needed for normal cellular pathways function, and testing the efficacy of newly developed drugs to target tumors lacking these genes.
Mechanistic and Therapeutic Studies of ZNRF3 Loss in Cancer
Cancer is fundamentally a problem of uncontrolled cell growth where there are either too many new cells being born or not enough old cells dying. Normally, networks of proteins known as ‘signaling pathways’ coordinate the proper balance between cell growth and cell death to prevent cancer from forming. However, many cancers disrupt this equilibrium by mutating genes that encode critical proteins required for these pathways to function.
To better understand the origins of cancer and design more effective therapeutic strategies, recent studies have focused on identifying all genes that are altered in each type of human cancer. The Cancer Genome Atlas Project led many of these multi-institutional efforts and implicated several new genes in cancer, including ZNRF3 and RNF43. These two highly related genes are inactivated, either by mutation or deletion, in a wide range of human cancers, including prostate, colon, ovarian, pancreatic and adrenal cancer. Previous studies have linked ZNRF3/RNF43 to a cellular pathway called Wnt signaling that is known to help control normal cell growth. However, the Wnt pathway splits into several different branches that each requires a specific type of cancer drug. Since ZNRF3/RNF43 are thought to function near the top of the pathway, it is unclear which branch of Wnt signaling is affected by ZNRF3/RNF43 loss.
To investigate the consequences of ZNRF3/RNF43 loss, I developed a genetically engineered mouse model that lacks ZNRF3 in the adrenal gland, one tissue where this gene is frequently altered in human tumors. Using the model, I aim to:
1) Determine how the loss of ZNRF3/RNF43 disrupts Wnt signaling
2) Test the efficacy of newly developed drugs predicted to target tumors lacking these genes
Ultimately, the long-term goal of my studies is to provide the framework necessary to develop new strategies for the treatment of a range of human cancers.
Summer 2019 Update from Dr. Katie Basham: In February 2019, Dr. Basham published a paper describing the mouse model of ZNFR3 loss that she generated. The ZNFR3 gene is frequently deleted in human adrenal tumors, and her work examines the effect this has on normal tissue homeostasis. Dr. Basham also presented on this topic at a conference in Munich, Germany in June 2018 where she received the New Investigator Award. Additionally, Dr. Basham was invited to present her work at a symposium during the Endocrine Society meeting in New Orleans in March 2019. She is currently using the mouse model to examine potential therapeutic strategies for the treatment of ZNFR3-altered tumors.
Dr. Basham has enjoyed becoming more involved with the American Cancer Society. Over the past year , she participated in her first Relay For Life event where she was a speaker during the opening ceremonies, and she joined the Michigan ResearcHERS campaign as an ambassador to help raise support for other women cancer researchers.
Find more information about Dr. Basham, including published work.
Dr. Jennifer Speth received her PhD in Microbiology and Immunology at Indiana University after completing her bachelor of Science in Microbiology at Ball State University in Muncie, Indiana. She is currently a Postdoctoral Translational Scholar Program fellow at the University of Michigan’s Department of Internal Medicine - Pulmonary and Critical Care Division.
Her research focuses on exploring use of a novel type of cell to cell communication as a strategy to inhibit tumor formation and progression in lung cancer.
Defining the Role of Alveolar Macrophage Secreted SOC3 in Lung Cancer
Lung cancer is the leading cancer killer in both men and women and has a five-year survival rate of only 18%. The majority of lung cancers arise from epithelial cells which are the structural cells that line the inside of the lung. Homeostatis is the balanced state where everything functions normally; lung cancer is thought to develop as a result of altered homeostasis and unrestrained inflammation in the lung environment. In the normal lung, homeostasis is maintained by communication between epithelial cells and the resident immune cell of the lung, the alveolar macrophage. The alveolar macrophage functions as the patroller or security guard in the lung. The alveolar macrophage communicates with epithelial cells to send signals to other cells when help is needed to clear infection, so it is very important that they communicate effectively to each other to manage the immune response effectively.
Recently, our lab discovered a novel type of communication in which alveolar macrophages release small “packages” termed microvesicles that contain a suppressive protein termed SOCS3. These vesicles can be taken up by epithelial cells and result in inhibition of inflammatory responses. In lung cancer, it is thought that low levels of SOCS3 within epithelial cells can promote inflammation and tumor formation. We speculate that acquisition of SOCS3 from alveolar macrophages may represent a “backup” source of this tumor suppressor in epithelial cells, but whether this process is disrupted in lung cancer is not known. Our preliminary data suggest that it is.
In my project, we will:
verify and determine the mechanisms of dysregulated alveolar macrophage SOCS3 secretion in lung cancer
explore the potential use of synthetic microvesicles containing SOCS3 as a therapeutic strategy to inhibit tumor formation and progression, both in human cancer cells and mouse models of lung cancer
conduct exploratory analysis of SOCS3 levels in samples from patients undergoing diagnostic procedures for lung cancer to assess correlations with cancer cell type and stage to suggest potential future biomarker studies
​
Summer 2018 Update from Dr. Speth: I am presently working on structural and biochemical studies of the metastatic protein P-Rex1 towards understanding how this protein is regulated in the body, particularly in cancer metastasis, which is the project that I was working on while funded by MCRF. Since our 2016 publication on this work in the journal Structure, we have made substantial breakthroughs on this project and will submit multiple manuscripts for publication within the next year. I am currently a research investigator at the University of Michigan in the labs of John Tesmer and Michael Cianfrocco where I am learning an exciting new technique called cryo-electron microscopy in order to address bigger picture questions on this project. Our labs just recently received and NIH R01 to continue this work. Right now, I am on the job market for a faculty position to start up my own lab, where I will be taking this project with me as well as pursuing other related projects focusing on cancer-implicated proteins and understanding regulation of their functions in the body. Having something as prestigious as an ACS-MCRF postdoctoral fellowship on my record has been very helpful in applying for these positions.
Brock Humphries, PhD | University of Michigan | Microfluidic-based Identification of Drivers of Tumor-initiating Cells
Kaitlin Basham, PhD | University of Michigan | Mechanistic and Therapeutic Studies of ZNRF3 Loss in Cancer
Jennifer Speth, PhD | University of Michigan | Defining the Role of Alveolar Macrophage Secreted SOC3 in Lung Cancer
Daryl Staveness, PhD | University of Michigan | Re-Engineering Toxic Aniline-Based Drugs with 1-Aminonorbornane Isosteres
Rochelle Tiedemann, PhD | Van Andel Research Institute | The Functional Role of Chromatin Marks for Enhancer Fidelity and Integrity
Hilary Marusak, PhD | Wayne State University | Neurobehavioral Correlates of Learning and Memory in Child Cancer Survivors
Ethan Abel, PhD | University of Michigan | The Role of HNF1A in Pancreatic Cancer Cell Biology
Karmanos Cancer Institute Institutional Research Grant (IRG) | This award funded pilot grants for nine investigators over three years.
Jennifer Cash, PhD | University of Michigan | Understanding Regulation of P-Rex1, an Enhancer of Metastatic Potential
Lauren Tanebe, PhD | Wayne State University | Targeting Matriptase/c-Met Signaling in Inflammatory Breast Cancer
Barbara Ann Karmanos Institute Block Grant | This award provide small pilot grants to new faculty to enable these beginning investigators to generate sufficient data in their new laboratories to make them competitive for national research grants.
Jeannie Hernandez, PhD | University of Michigan | Regulation of Cell Polarity and Tumor Suppression by Dynamic Palmitoylation
Kristen Admiraal, MSW | Michigan State University | Quality of Life Outcomes Among Older Adults with Colorectal Cancer
Aaron Van Dyke, PhD | University of Michigan | Modulating Androgen Receptor with Bifunctional Recruiters
Kurt Januszyk, PhD | Memorial Sloan-Kettering Cancer Center | Investigations into How the Exosome Recognizes and Degrades RNA
David DeGraff, PhD | Pennsylvania State University | Role of Foxa1 Binding Partners in Androgen Regulated Prostate Cancer
Welcome to the Michigan Cancer Research Fund (MCRF)
The MCRF was established in 2008 by a group of cancer-concerned philanthropists to fund approved critical cancer research projects that would otherwise remain unfunded.
Enter Content Here
The American Cancer Society conducts long-term studies that help us better understand the causes of cancer and how to prevent the disease. These studies have shown how lifestyle, environmental, genetic and other factors relate to cancer risk and how they ultimately played a role in the 29% drop in cancer death rates between 1991 and 2017.
The American Cancer Society funds scientists who conduct research about cancer at medical schools, universities, research institutes, and hospitals throughout the United States. We use a rigorous and independent peer review process to select the most innovative research projects proposals to fund. To-date, the Society has invested more than $300 million, funding 550 grants. Initial investigations focused on gathering data to document that health inequities exist; then studies moved to identifying the multi-factorial causes; since 2013, the focus has been on solution-based strategies.
current funding totals as of August 1, 2021
The American Cancer Society awarded over $16 million in grants to establish Cancer Health Equity Research Centers (CHERC) at Minority Serving Institutions (MSIs) in 2022.
The inaugural cohort of institutions includes the Arizona Board of Regents – University of Arizona; the University of Illinois at Chicago; Morehouse School of Medicine and Howard University. Each institution received a four-year grant of $4.08 million.
The institutions selected in the initial cohort will implement solution-based research addressing cancer health disparities that will contribute to achieving health equity and reducing cancer mortality.
|
University of Kentucky Diversity in Cancer Research Internship Recipients from 2021. |
Diverse perspectives in research are an essential component of driving innovative problem-solving that accelerates new approaches to the prevention and treatment of cancer. To improve diversity in the field of cancer research, the American Cancer Society launched a new grant program awarding funding to universities to implement its Diversity in Cancer Research (DICR) Internship program.
Made possible by a $5 million grant from the Elizabeth and Phil Gross Family, the American Cancer Society DICR pilot launched in 2021 with 32 interns at Emory University, Georgetown University, the University of Chicago, the University of Colorado, the University of Kentucky, the University of Maryland, the University of New Mexico, and Washington University. The goal of the DICR Internship program is to enroll 100 interns per year over ten years.
In 2022, 12 universities are receiving DICR Internship grants, including: Yale University School of Medicine; Emory University; Case Western Reserve University; the University of Chicago; Indiana University; University of Kentucky Research Foundation; University of Colorado Denver Anschutz Medical Campus; University of New Mexico Health Sciences Center; Georgetown University; Board of Regents of the University of Oklahoma Health Sciences Center; University of Maryland, Baltimore; and Washington University in St. Louis. |
The success of the American Cancer Society grant program is exemplified by the fact that 50 American Cancer Society-funded researchers have received a Nobel Prize for their work. |
Carolyn Bertozzi, PhD, was one of three scientists to be awarded the 2022 Nobel Prize in Chemistry for the development of click chemistry and bio-orthogonal chemistry. She is the 50th American Cancer Society-funded researcher and the first woman researcher funded by ACS to win the prestigious honor. Learn more about her work. |
The American Cancer Society Cancer Action Network (ACS CAN) is the nonprofit, nonpartisan advocacy affiliate of the American Cancer Society. Its role is to support evidence-based policy and legislative solutions designed to eliminate cancer as a major health problem. American Cancer Society (ACS) researchers collaborate with ACS CAN staff to explore how and why certain groups of people in the US are not benefitting from health care services such as cancer prevention, early detection, and treatment.
ACS CAN is attacking disparities by changing or adding new evidence-based public health policies at the local, state, and federal levels. The goal of ACS CAN is to reduce these disparities and improve health outcomes for all US population groups regardless of race, ethnicity, gender, age, sexual orientation, socioeconomic status, or zip code.
Welcome to the Michigan Cancer Research Fund (MCRF)
The MCRF was established in 2008 by a group of cancer-concerned philanthropists to fund approved critical cancer research projects that would otherwise remain unfunded.
Welcome to the Michigan Cancer Research Fund (MCRF)
The MCRF was established in 2008 by a group of cancer-concerned philanthropists to fund approved critical cancer research projects that would otherwise remain unfunded.
If you are interested in learning more about the Michigan Cancer Research Fund,
contact the American Cancer Society at MCRF@cancer.org.